Total amount: € 0,00
Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,014
Online ISSN 1827-1820
Baranzoni N. 1, Scalone L. 2,3, Mantovani L. G. 2,3, De Portu S. 3, Monzini M. S. 2, Giannetti A. 1
1 Department of Dermatology Polyclinic Hospital University of Modena and Reggio Emilia, Modena, Italy
2 Center of Pharmacoeconomics Department of Pharmacological Sciences University of Milan, Milan, Italy
3 CIRFF – Cenet of Pharmacoeconomics Federico II University, Naples, Italy
Aim. To test psychometric properties of the Italian version of Infants’ Dermatitis Quality Of Life Index (IDQOL) and Family Dermatitis Index (FDI).
Methods. Parents of 21 children with atopic dermatitis were recruited at the Polyclinic Hospital in Modena and interviewed on two separate occasions. We tested: feasibility, by computing the number of missing answers; reliability, by testing internal consistency and test-retest reproducibility; agreement between the FDI and the IDQOL and of these with the parent-reported severity score and SCORAD.
Results. All respondents answered to every question. All the scores were similar in the two interviews. In both interviews the parent-reported severity score had a median of 1.00 (0-3), the median total IDQOL score was 9, the median FDI score 5. Intraclass correlation coefficient was 0.95 in IDQOL and 0.99 in FDI, the presence of biases excluded. Level of agreement of each item between the two interview was satisfactory, with values of the weighted kappa coefficients ranging from 0.63 to 1.00. Cronbach’s alpha coefficient for internal consistency was >0.7 in IDQOL and >0.9 in FDI. The agreement between IDQOL and FDI was significant (P<0.0001) and so do the agreement between these indexes and parent-reported severity score (P<0.05) and SCORAD (P<0.01).
Conclusion. The Italian version of IDQOL and FDI has satisfactory psychometric properties and can be used to evaluate quality of life of infants with atopic dermatitis and their families. These instruments used together with clinical instruments can help physicians and policy makers in decisions on patients’ treatment and health care resource allocation.